tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

NLS Pharmaceutics and Kadimastem Secure Hong Kong Patent for Diabetes Therapy

Story Highlights
  • NLS Pharmaceutics and Kadimastem received a Hong Kong patent for IsletRx technology.
  • The patent strengthens IP protection in Asia, aiding future collaborations and commercialization.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
NLS Pharmaceutics and Kadimastem Secure Hong Kong Patent for Diabetes Therapy

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

NLS Pharmaceutics ( (NLSP) ) just unveiled an update.

On September 4, 2025, NLS Pharmaceutics and its merger partner Kadimastem announced the granting of a Hong Kong patent for a cell-selection and enrichment technology used in IsletRx, a stem cell-derived therapy candidate for insulin-dependent diabetes. This patent expands the intellectual property protection in Asia, complementing existing patents in Europe, the United States, and India, and supports the long-term strategy for IsletRx. The move is significant given Hong Kong’s role as a gateway to Mainland China and its substantial diabetes market, potentially impacting future clinical collaborations and commercialization efforts.

More about NLS Pharmaceutics

NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and related indications.

Average Trading Volume: 246,744

Technical Sentiment Signal: Sell

Current Market Cap: $7.41M

For detailed information about NLSP stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1